25 nov: Matas mærker stigende interesse blandt kunderne på Black Friday -..
25 nov: Shipping: Baltic Dry-indekset falder 1,7 pct. til 1181 point
25-11-2016 14:07:32

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
14 sep - 
Aktier/tendens: Luftfartsaktier kan komme flyvende fra ..
05 sep - 
Tirsdagens aktier: Mærsk og Danske Bank spændte ben for..
25 aug - 
Fredagens aktier: Genmab-investorer trak gevinster hjem
Relateret debat
21 sep - 
Gratis ordningen må kun brukes indtil der er en forsikr..
21 sep - 
Sådan som jeg læser formmulary lookup mangler Sanofi at..
21 sep - 
Ok, tak.

Company announcement - No. 47 / 2016

 

 

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 25 November 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 57,913 divided into 57,913 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under three of Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 per share for 35,851 of the new shares, DKK 50.27 per share for 17,062 of the new shares and DKK 87.45 per share for 5,000 of the new shares. The total proceeds to Zealand from the capital increase amounts to DKK 4,055,483.74.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,128,366 divided into 26,128,366 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) in the United States, and in Europe a CHMP positive opinion recommendation was given on 11 November. Suliqua(TM) is the brand name in Europe.

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

47-16_1125 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771857.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 sep
ZEAL
CEO Oliver Brandicourt fra Sanofi deltog i Morgan Stanley’s Global Healthcare Conference d. 12. sept..
8
19 sep
ZEAL
Læse regnskaber fem år tilbage? Det er da nok den analysemetode der giver allermindst mening ift. bi..
2
19 sep
ZEAL
Hvor har en loppe ingen bukser? Hvorfor er den lille fisk så våd? Hvorfor bli’r en kylling ikke malk..
1

Pandora: Amerikansk investeringsselskab øger igen short-position

25-09-2017 15:17:33
Endnu engang har det amerikanske investeringsselskab AQR Capital Managment øget sin andel af såkaldte "shortede" aktier i smykkeselskabet Pandora.Det fremgår af en indberetning til Finanstilsynet.AQR Capital Managment har nu en shortposition i Pandora på 2,1 pct., hvor investeringsselskabet tidligere kun ejede 2 pct. af den samlede udstedte aktiekapital i selskabet.Mandag eftermiddag stiger Pandor..

NKT/Jyske: Triton Knoll-ordre vil give god sigtbarhed i Köln i 2019

25-09-2017 14:25:53
NKT er i favoritposition til at løbe med kabelkontrakten til det britiske havvindmølleprojekt Triton Knoll, efter at udviklerne bag, et joint venture mellem Innogy og Statkraft, har valgt den danske leverandør som den foretrukne.Kommer der i løbet af 2018 som ventet en fast og ubetinget aftale ud af det, så vil det sammen med en eventuel ordre på Borssele beta sikre NKT en god kapacitetsudnyttelse..

Aktier/middag: Nets rider på købsbølgen i let positivt marked

25-09-2017 11:43:44
Nets er den store historie på ugens første dag på fondsbørsen, efter at en amerikansk kapitalfond har lanceret et købstilbud på 33 mia. kr.Et køb har været rygtet i længere tid, men mandag blev det altså officielt, at fonden Hellman and Friedman vil købe hele Nets. Det sender aktien i betalingsselskabet i vejret.Samlet set er aktiehumøret i både Danmark og Europa lunet op i dagens løb, så det tone..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestjysk Bank: Investorgruppe har allerede tjent 3 mia. kr. - citat
2
Aktier/tendens: Købsrygterne svirrer om Nets igen
3
Aktier/middag: Nets rider på købsbølgen i let positivt marked
4
Pandora: Amerikansk investeringsselskab øger igen short-position
5
Verdens største kapitalforvalter ser stort på kinesisk nedjustering

Relaterede aktiekurser

Zealand Pharma A/S 116,50 0,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. september 2017 18:50:07
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170925.1 - EUROWEB3 - 2017-09-25 18:50:07 - 2017-09-25 18:50:07 - 1 - Website: OKAY